Abbott’s COVID-19 laboratory-based antibody tests to be available in India by May-end

By: |
Updated: May 04, 2020 3:40 PM

The company will begin shipping the tests to India during May and will scale up to meet the demands subsequently, Abbott said in a statement.

Abbott, COVID-19 laboratory, antibody tests, COVID-19 cases, COVID-19 tests, covid 19 test laboratory, latest news on coronavirus outbreakAbbott has long been a global leader in infectious disease testing, including the development of the first HIV test. (Representational image: IE photo)

Global healthcare major Abbott on Monday said it has received CE mark for its laboratory-based serology blood tests for COVID-19 and these tests will be available in India by the end of May.

The company will begin shipping the tests to India during May and will scale up to meet the demands subsequently, Abbott said in a statement.

“Abbott has been singularly focused on bringing COVID-19 tests to market as quickly as possible to help address this pandemic. We are proud to be providing our antibody tests in the coming weeks as they will help understand who has had the virus, leading to greater confidence as we get to living life,” Abbott’s diagnostics business in India General Manager and Country Head Narendra Varde said.

Also read| Check latest updates here:

Antibody testing is an important step to tell if someone has been previously infected. It will provide more understanding of the virus including how long antibodies stay in the body and if they provide immunity, the statement said.

This type of knowledge could help support the development of treatments and vaccines, it added. Abbott has long been a global leader in infectious disease testing, including the development of the first HIV test.

Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Financial Express is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.

Next Stories
1Won’t release vaccine for mass use, unless vaccine is proved immunogenic and safe: SII
2Coronavirus India updates: Active Covid-19 cases shrink to 4.6% of total positive cases; cumulative positivity rate 6.69%
3Supreme Court says will clarify position on homeopathic preventive treatment for COVID, reserves verdict